HMG-CoA还原酶抑制剂与神经病变的关联。
Association of HMG-CoA reductase inhibitors with neuropathy.
作者信息
Backes James M, Howard Patricia A
机构信息
Department of Pharmacy Practice and Lipid, Atherosclerosis, Metabolic and LDL-Apheresis Clinic, University of Kansas Medical Center, Kansas City, KS 66160-7231, USA.
出版信息
Ann Pharmacother. 2003 Feb;37(2):274-8. doi: 10.1177/106002800303700220.
OBJECTIVE
To review the possible association between statins and peripheral neuropathy.
DATA SOURCES
Literature was obtained from MEDLINE (1984-September 2002) and International Pharmaceutical Abstracts (1970-June 2002). Key search terms included statin, neuropathy, and HMG-CoA reductase inhibitor.
DATA SYNTHESIS
Epidemiologic studies and case reports suggest an increased risk of peripheral neuropathy with statin drugs. Most patients were receiving long-term therapy, although the onset was highly variable. The majority of cases were at least partially reversible with drug cessation. Specific risk factors or mechanisms have not been identified.
CONCLUSIONS
Observational data suggest a link between chronic statin use and increased risk of peripheral neuropathy. However, the risk appears to be small relative to the significant cardioprotective benefits.
目的
回顾他汀类药物与周围神经病变之间可能存在的关联。
资料来源
文献取自医学索引数据库（1984年至2002年9月）和国际药学文摘数据库（1970年至2002年6月）。关键检索词包括他汀类药物、神经病变和HMG-CoA还原酶抑制剂。
资料综合
流行病学研究和病例报告表明，使用他汀类药物会增加周围神经病变的风险。大多数患者接受的是长期治疗，尽管发病情况差异很大。大多数病例在停药后至少部分可逆转。尚未确定具体的危险因素或机制。
结论
观察性数据表明，长期使用他汀类药物与周围神经病变风险增加之间存在联系。然而，相对于显著的心脏保护益处而言，这种风险似乎较小。
Zotero 插件